The facts about participating in clinical research and our ongoing studies:
First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.
Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.
For more information, please call: 954-366-0277.
CURRENTLY ENROLLING CLINICAL TRIALS
HOLLYWOOD NEUROLOGY
To participate or refer a patient, call 954-366-0277; Ext 120 – Jorge, Ext 121 – Rebecca, Ext 124 – Lucy.
Clinical Coordinators: Jorge Riveros, IMG, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC
Lilly: Trailblazer 3-AACM Preclinical Memory Loss – Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of Donanemab in Preclinical Alzheimer’s Disease for people 55-80 years of age, not yet diagnosed with memory problems.
Jazz: EveresT Essential Tremor – A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential Tremor for people 18-80 years of age.
Sage: Essential Tremor – A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor in adults with mild to moderate bilateral tremor for at least 3 years. Ages 18-80.
Biogen Envision: Alzheimer’s Disease – A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease, ages 60-85.
Lilly: 15T-MC-AACQ Alzheimer’s Disease – Investigating the effect of different Donanemab dosing regimens on ARIA-E and amyloid lowering in adults with early symptomatic Alzheimer’s Disease. Ages 60-85.
SUNRISE OFFICE NEUROLOGYTo participate or refer a patient Call 954-475-8171, ext 146 (Maria) or ext 134 (Muskaan)
Clinical Coordinators: Maria Gonzalez, RMA, CCRC and Muskaan Ochani, BS, CRC
Cassava: Alzheimer’s Disease – A Phase 3, Double-blind, Pacebo controlled 52-Week study evaluating the safety and efficacy of Simufilam 100 mg tablets in subjects with Mild to Moderate Alzheimer’s Disease in patients age 50-87
Axsome: Migraine – An open label, multidose evaluation of the efficacy and safety of AXS-07 (Meloxican and Rizatriptan) for the Acute treatment of Migraine in adult with an inadequate response to oral CGRP inhibitors. Patients over 18 years of age.
Axsome: Alzheimer’s with Agitation ADVANCE-2 – A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer’s Disease Agitation for 6 weeks, followed by an Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Dementia of the Alzheimer’s Type ages 65-90.
SUNRISE OFFICE NEUROLOGY – MS STUDIES
To participate or refer a patient –Call 954-475-8171 Ext 134 (Muskaan)
Novartis: COMB157GUS12 – An open-label multicenter study to assess response to influenza vaccine in participants with multiple sclerosis treated with ofatumumab 20 mg subcutaneously for people 18-55 years of age.
Biogen: Fusion-RMS – A two-part, multicenter, randomized, blinded, active-controlled Phase 2 study to sequentially evaluate the safety and efficacy of BIIB091 (BTK inhibitor) Monotherapy and BII091 Combination Therapy with Diroximel Fumarate in participants with relapsing forms of Multiple Sclerosis. Ages 18-55.
